Tag:

Novo Nordisk

Latest Headlines

Latest Headlines

Novo will soon open plant in Russia

The Russian ruble maybe in rubble, but the economic challenges will not deter Novo Nordisk, which is finishing up a plant in Russia. Five years in the planning and nearly three in construction, execs say it is needed to fulfill the drugmaker's long-term goals there.

Novo Nordisk puts 500 Saxenda reps on U.S. streets, aiming for $1B in weight-loss sales

Novo Nordisk has set its Saxenda target and enlisted its U.S. sales force. Now it just needs to follow through--and that won't be an easy task.

Novo hopes for European Saxenda launch this year after CHMP nod

Novo Nordisk's obesity therapy Saxenda is on a roll. Just over a month after snagging FDA approval, the drug scored a positive recommendation on Thursday from Europe's Committee for Medicinal Products for Human Use (CHMP). But by the time it gets to the regulatory finish line, the med may have some competition on the continent.

'Crown prince' Schultz not a sure bet for Novo CEO as Sørensen's contract nears end

With Novo Nordisk's chief exec Lars Rebien Sørensen's contract expiring within the next few years, the company's board is scouting his replacement. And as soon as they name one, Sørensen says he's ready to make a quick exit.

Novo Nordisk kick-starts its obesity franchise with a long-awaited FDA nod

Two months after its self-imposed deadline, the FDA finally signed off on Novo Nordisk's first weight-loss therapy, a milestone for the company as it blueprints a future in obesity.

Novo Nordisk gets EU recommendation for Tresiba use in kids

Novo Nordisk has a while yet to wait for another shot at FDA approval for Tresiba, a drug on which it has pinned its future, but it continues win support for it in Europe.

Novo Nordisk shrinks executive team as top-ranking woman leaves

Novo Nordisk says it has reorganized its executive team, with EVP Lise Kingo making an exit and her duties divvied up among the company's remaining top execs.

GSK, Novo earn top marks getting their meds to poor, but more work lies ahead

Big Pharma earned gold stars in 2014, as the industry's top drugmakers did more to get their meds to patients in the world's poorest countries. But despite recent progress, companies still have room to grow in R&D and distribution, the Index notes.

Will GLP market growth save Novo's Victoza from Lilly's new Trulicity?

When a new drug bursts upon an established drug class, the established players often wave away worries about market share. Sales for the whole class will grow, they say, because we'll have one more company on the street promoting it. And when it comes to Eli Lilly's Trulicity, the brand-new GLP-1 diabetes treatment, even Lilly says so.

Novo Nordisk builds blockbuster case with promising PhIII obesity data

In new late-stage data, Novo Nordisk's inaugural obesity drug spurred statistically significant weight loss compared to placebo, bolstering the company's case as it works to build a portfolio of such treatments.